Introduction {#s1}
============

Toll-like receptors (TLRs) are a class of highly conserved membrane bound pattern recognition receptors (PRRs) that play an integral role in the regulation of the immune system through the recognition of pathogen-associated molecular patterns (PAMPs) and the activation of immune response genes \[[@B1],[@B2]\]. Toll-like receptor 4 (TLR4), is a well-studied TLR, specifically recognizing lipopolysaccharide from Gram-negative bacteria \[[@B3],[@B4]\] and initiating intracellular signal cascades, that involve the adaptor protein encoded by the myeloid differentiation primary response gene 88 (MyD88), which ultimately activates nuclear factor kappa B \[[@B5]\] and leads to interferon production \[[@B6]\]. TLR4 has also been shown to recognize mannans of fungal pathogens \[[@B7]\], *Mycobacterium tuberculosis* \[[@B8]\], and the fusion protein of respiratory syncytial virus \[[@B9]\].

Two single nucleotide polymorphisms (SNPs), *TLR4* 896 A\>*G* (corresponding to an Asp299Gly substitution mutation ; SNP ID: rs 4986790) and *TLR4* 1196 C\>*T* (corresponding to a Thr399Ile substitution mutation; SNP ID: rs 4986791), have been shown to be associated with LPS hyporesponsiveness \[[@B10],[@B11]\]. In whites, the two SNPs are in linkage disequilibrium (D=1 and r2=0.791, HapMap accessible at: [[http://hapmap.ncbi.nlm.nih.gov/]{.ul}](http://hapmap.ncbi.nlm.nih.gov/)). Structurally, these mutations are found outside of the ligand binding domain of TLR4 and crystal structures have shown that these mutations have no effect on LPS binding. Instead, they do cause local conformational changes around the area of the mutation that may affect folding efficiency, cell surface expression, protein stability, as well as interaction with downstream messenger proteins \[[@B12]\]. At the molecular level, it has been shown that the *TLR4* 896 A\>*G* mutation interferes with TLR4 interaction with MyD88 and other downstream messengers \[[@B13]\]. These mutations also appear to affect the levels of functional TLR4 expression, leading to a 2-fold reduction \[[@B14]\]. This reduction is further amplified to 10-fold in the absence of myeloid differentiation factor 2 (MD-2) which forms a complex with TLR4 and LPS \[[@B14],[@B15]\].

There has been great interest regarding the association of the TLR4 SNPs *TLR4* 896 A\>*G* and *TLR4* 1196 C\>*T* to susceptibility for infection and other non-infectious disease states. Clinical studies associating these SNPs to infectious disease susceptibility have produced mixed results \[[@B16]-[@B19]\]. The present study aims to reassess the association of *TLR4* 896 A\>*G* and *TLR4* 1196 C\>*T* with infectious disease susceptibility using the Generalized Odds Ratio (OR~G~), which can elucidate the magnitude and association of individual genotypes with susceptibility to disease \[[@B20]\].

Materials and Methods {#s2}
=====================

Study Selection {#s2.1}
---------------

We conducted searches on Pubmed and EMBASE up to March, 2013 (last access on March 3, 2013). The search terms included: "(toll AND like AND receptor AND 4 AND polymorphism) OR (TLR4 AND polymorphism) OR Asp299Gly OR D299G OR Thr399Ile OR T399I" for PubMED; "(\'tlr4\'/exp OR \'tlr4\') AND (\'receptor\'/exp OR \'receptor\') AND (polymorphism OR asp299gly OR d299g OR thr399ile OR t399i)" for EMBASE. The titles and abstracts of the studies were reviewed; titles that included TLR4 polymorphisms and risk for infectious disease were included for more detailed evaluation. Studies that reviewed TLR4 polymorphisms and their association with non-infectious disease were excluded, as were studies that were not published in English. An eligible study fulfilled all of the following three criteria: (i) the study reported an infectious disease outcome, (ii) the study was performed using a case-control design, where "cases" refer to subjects with a disease outcome and controls refer to a healthy population (without the disease outcome), and, (iii) the study reported genotype frequencies for *TLR4* 896 A\>*C*, *TLR4* 1196C\>*T*, or both.

Data Extraction {#s2.2}
---------------

Two authors (PDZ and MLP) independently extracted data from the final included articles. Any discrepancies were reviewed and resolved by consensus. The information extracted included name of first author, origin of population being studied, number of cases and controls being studied subdivided by genotype frequencies (homozygous wild-type, heterozygous, and homozygous mutant), the disease being studied, and the conclusions reportedly drawn from each study.

Data Synthesis {#s2.3}
--------------

We used the generalized odds ratio (OR~G~) along with its 95% Confidence Interval (95% CI) to address the association of *TLR4* 896 A\>*C* and *TLR4* 1196 C\>*T* polymorphisms with outcomes of interest (disease susceptibility). The OR~G~ provides a model-free approach of estimating the genetic risk in genetic association studies (GAS) and meta-analysis of GAS, depending on the mutational load \[[@B20]\]. The OR~G~ is defined as follows: for any two subjects, one diseased (case) and one non-diseased (control), the OR~G~ estimates the odds of being diseased relative to the odds of being non-diseased when the diseased subject has higher mutational load than the non-diseased subject, i.e. the risk of disease is proportional to the increased genetic exposure. Alternatively, the OR~G~ shows how many diseased-healthy pairs exist in the study for which the diseased have the larger mutational load, relative to the number of pairs for which the non-diseased have the larger mutational load \[[@B20]\]\[[@B21]\]. The OR~G~ estimates the overall genetic risk effect by utilizing the complete genotype distribution whereas the OR of conventional genetic models (additive, dominant, recessive, co-dominant) is calculated by merging genotypes. In addition, the conventional genetic models are not independent and thus, the interpretation of results is difficult when more than one model is significant \[[@B22]\]. In the meta-analysis of GAS, heterogeneity was quantified using the Cochran's Q and I^2^ metric \[[@B20]\]. The existence of the differential magnitude of effect in large versus small studies was checked using the Harbord's test \[[@B23]\] for meta-analysis involving at least four studies. Also, the Hardy-Weinberg equilibrium (HWE) was used as a quality criterion for control populations. HWE deviations may result in biased estimations as they can influence type-I error in single study effects, and may alter statistical significance in meta-analysis of gene-disease associations \[[@B24],[@B25]\]. The HWE deviations amongst the control populations were screened using the chi-square test \[[@B26]\]. For single studies deviating from HWE, a sensitivity analysis was performed after correction of control group with the expected genotype frequencies \[[@B22],[@B27]\]. ORG was calculated using the ORGGASMA application available at [[http://biomath.med.uth.gr]{.ul}](http://biomath.med.uth.gr) \[[@B20]\]. This study complies with the PRISMA guidelines for reporting reviews and meta-analyses ([Checklist S1](#pone.0081047.s001){ref-type="supplementary-material"}) \[[@B28]\].

Results {#s3}
=======

A total of 962 studies from PubMed and 1615 from EMBASE were initially retrieved, comprising a total of 2,197 non-duplicate studies ([Table S1](#pone.0081047.s002){ref-type="supplementary-material"}-Flow diagram). After reading the title and the abstract, 117 studies were found to be suitable for further evaluation. Of the 117 articles reviewed in detail, 58 studies were excluded (18 studies did not publish genotypic frequencies, 13 had no healthy controls in their experimental design, 5 focused on in vitro functional studies, 8 did not study the desired polymorphisms, 6 were either reviews or a meta-analysis, and 8 studies had non extractable data for other reasons). A total of 59 case-control studies \[[@B29]-[@B87]\] were included in the analysis, reporting 37 different disease outcomes ([Tables 1](#pone-0081047-t001){ref-type="table"} and [2](#pone-0081047-t002){ref-type="table"}). The origin of studies was in descending order Europe (28 studies), Asia (12 studies), South America (7 studies), Africa (6 studies), North America (5 studies), Australia (1 studies).

10.1371/journal.pone.0081047.t001

###### Genotypic frequencies reported for the *TLR4* 896 A\>*G* SNP and association with disease outcome; significant effects are in bold; outcomes that have been studied more than once have been grouped together in the table, with the overall effect described in the shaded area^***†***^ genotypic frequencies of controls that did not satisfy Hardy Weinberg Equilibrium, \[effects in brackets after correction of HWE deviations\].

                                                        Control Genotype   Case Genotype                                                                                                         
  ------------------------------------ ---------------- ------------------ --------------- ---- ----- ----- ---- ------------------------------------------ ------------------------------------ ------------------------------------------
  Carvalho et al \[[@B29]\]            England          70                 10              0    58    18    0    Aspergillosis                              Overall susceptibility not studied   2.10 (0.92-4.81)
  Rezazadeh et al \[[@B30]\]           Iran             65                 46              0    68    127   3    Brucellosis                                Increased risk**^*†*^**              2.66(1.66-4.27) \[**2.69 (1.67-4.33**)\]
  Doorduyn et al \[[@B31]\]            Netherlands      608                72              3    405   49    1    Campylobacter                              No association                       1.00 (0.68-1.46)
  Plantinga et al \[[@B32]\]           Tanzania         99                 9               0    107   10    0    Oropharyngeal candidiasis in HIV           No association                       1.02(0.41-2.55)
  Laisk et al \[[@B33]\]               Estonia          287                35              1    61    9     0    *C.trachomatis*(women)                     No association                       1.24 (0.58-2.67)
  Szebeni et al \[[@B34]\]             Hungary          108                10              0    37    4     0    NecEnterocolitis in LBW infants            No association                       1.26 (0.40-4.00)
  Lee, et al \[[@B35]\]                United States    431                11              21   103   2     3    Gram --ve infections in liver transplant   No association**^*†*^**              0.66 (0.26-1.70) \[0.42(0.16-1.66)\]
  Ajdary, et al \[[@B36]\]             Iran             73                 2               0    102   26    0    Leishmaniasis (Cutaneous)                  Increased risk                       **7.22 (1.91-27.29)**
  Rasouli et al \[[@B37]\]             Iran             137                18              0    110   11    1    Leishmaniasis (Visceral)                   No asscociation                      0.81 (0.38-1.75)
  Bochud et al \[[@B38]\]              East Africa      155                37              2    375   32    2    Leprosy                                    Protective                           0.36 (0.22-0.60)
  West, et al \[[@B39]\]               Thailand         1377               20              1    484   5     0    Meliodosis                                 No association**^*†*^**              0.74(0.29-1.92) \[0.70(0.27-1.78)\]
  Verma, et al \[[@B40]\]              India            127                22              1    77    61    2    Neurocysticercosis                         Increased risk                       **4.39(2.53-7.61)**
  Montes et al \[[@B41]\]              Spain            135                20              0    65    12    3    Osteomyelitis                              Increased risk                       1.55 (0.76-3.20)
  Emonts et al \[[@B42]\]              Netherlands      374                58              1    293   42    2    Otitis media (acute)                       Overall susceptibility not studied   0.96 (0.63-1.45)
  Moens et al \[[@B43]\]               Belgium          161                16              1    84    13    2    Invasive pneumococcal infection            No association                       1.69 (0.81-3.54)
  Mrazek et al \[[@B44]\]              Czechoslovakia   217                34              1    89    9     0    Prosthetic joint infection                 No association                       0.66 (0.31-1.42)
  Doorduyn et al \[[@B31]\]            Netherlands      608                72              3    173   20    0    *Salmonella* gastroenteritis               No association                       0.96 (0.57-1.60)
  Yuan et al \[[@B45]\]                Australia        364                44              1    82    3     0    *S. pneumoniae*                            Protective                           0.35 (0.12-1.07)
  Liadaki, et al \[[@B46]\]            Greece           195                27              0    99    6     0    Tonsillar Disease (*H.influenzae*)         No association                       0.47 (0.19-1.14)
  Liadaki, et al \[[@B46]\]            Greece           264                25              0    30    8     0    Tonsillar Disease (*S.pyogenes*)           Increased risk                       **2.93 (1.24-6.93)**
  Bhuvanendran, et al \[[@B47]\]       Malaysia         241                9               0    277   27    0    Typhoid Fever                              Increased Risk                       **2.51 (1.18-5.34)**
  Yin, et al \[[@B48]\]                China            227                21              0    109   20    0    UTI (Adults)                               Increased risk                       **1.98 (1.04-3.98)**
  Hawn et al \[[@B49]\]                United States    274                33              6    585   65    2    UTI (Women)                                No association                       0.79 (0.52-1.20)
                                                                                                                 **Chagas Disease**                                                              1.06 (0.53-2.14)
  Weitzel, et al \[[@B50]\]            Northern Chile   42                 3               0    114   11    0    Chagas Disease                             No association                       1.20 (0.35-4.14)
  Zafra et al \[[@B51]\]               Colombia         191                9               0    262   10    3    Chagas Disease                             No association                       1.00 (0.43-2.36)
                                                                                                                 ***H. pylori***                                                                 0.91 (0.61-1.36)
  Achyut et al \[[@B52]\]              India            168                32              0    110   20    0    *H. pylori*                                No association                       0.97 (0.53-1.76)
  Moura et al \[[@B53]\]               Brazil           222                28              4    206   25    1    *H. pylori*                                No association**^*†*^**              0.87(0.50-1.50) \[0.81(0.47-1.40)\]
                                                                                                                 **Malaria**                                                                     **1.31 (1.04-1.66)**
  Esposito, et al \[[@B54]\]           Burundi          300                36              1    528   72    2    Malaria (children)                         No association                       1.13 (0.74-1.73)
  Zakeri, et al \[[@B55]\]             Iran             287                33              0    276   39    5    Malaria (all ages)                         No association                       1.38 (0.86-2.22)
  Mockenhaupt et al \[[@B56]\]         Ghana            239                47              4    444   129   7    Malaria (pregnancy)                        Overall susceptibility not studied   1.42 (0.99-2.02)
                                                                                                                 **Meningococcal disease**                                                       1.10 (0.90-1.34)
  Biebl et al \[[@B57]\]               Austria          678                88              3    167   18    0    Meningococcal disease (all ages)           No association                       0.82 (0.49-1.40)
  Read et al \[[@B58]\]                England          787                81              11   924   110   13   Meningococcal disease (all ages)           No association**^*†*^**              1.13 (0.86-1.51) \[1.05(0.79-1.38)\]
  Faber et al \[[@B59]\]               Europe           190                23              1    165   27    5    Meningococcal disease (infants)            Increased risk                       1.55(0.89-2.72)
  Allen et al \[[@B60]\]               Gambia           198                51              2    198   51    3    Meningococcal meningitis (children)        No association                       1.02(0.67-1.56)
                                                                                                                 **Periodontitis (aggressive)**                                                   1.04 (0.53-2.04)
  Brett et al \[[@B61]\]               England          90                 7               0    37    8     0    Aggressive periodontitis                   No association                       2.73 (0.96-7.76)
  Emingil et al \[[@B62]\]             West Europe      147                7               1    86    4     0    Aggressive periodontitis                   No association**^*†*^**              0.96 (0.30-3.12) \[0.81(0.26-2.54)\]
  James et al \[[@B63]\]               West Europe      103                20              0    69    4     0    Aggressive periodontitis                   No association                       0.33 (0.12-0.97)
  Noack et al \[[@B64]\]               Germany          71                 9               0    100   11    0    Aggressive periodontitis                   No association                       0.86 (0.35-2.13)
  Schulz et al \[[@B65]\]              Germany          73                 7               0    52    8     0    Aggressive periodontitis                   No association                       1.58 (0.56-4.47)
                                                                                                                 **Periodontitis (chronic)**                                                     0.94 (0.75-1.18)
  Garlet, et al \[[@B66]\]             Brazil           131                74              12   135   56    6    Chronic periodontitis                      No association                       0.70 (0.47-1.03)
  Noack et al \[[@B67]\]               Germany          68                 8               0    96    12    0    Chronic periodontitis                      No association                       1.04 (0.42-2.61)
  Sahingur et al \[[@B68]\]            United States    59                 17              1    95    19    0    Chronic periodontitis                      No association                       0.67 (0.33-1.37)
  Schulz et al \[[@B65]\]              Germany          73                 7               0    66    7     0    Chronic periodontitis                      No association                       1.10 (0.38-3.19)
  Izakovicova Holla et al \[[@B69]\]   Czechoslovakia   195                23              0    147   24    0    Chronic periodontitis                      No association                       1.38 (0.76-2.53)
  Berdeli et al \[[@B70]\]             Turkey           100                6               0    79    4     0    Chronic periodontitis                      No association                       0.88 (0.26-3.01)
  James et al \[[@B63]\]               West Europe      78                 16              0    77    17    1    Chronic periodontitis                      No association                       1.11 (0.53-2.31)
  Brett et al \[[@B61]\]               England          90                 7               0    47    6     0    Chronic periodontitis                      No association                       1.66 (0.55-4.97)
  Laine et al \[[@B71]\]               Netherlands      90                 8               1    90    10    0    Chronic periodontitis                      No association                       1.16 (0.46-2.93)
  Folwaczny et al \[[@B72]\]           Germany          236                8               0    234   10    0    Chronic periodontitis                      No association                       1.24 (0.50-3.12)
                                                                                                                 **Respiratory Syncytial Virus**                                                 1.02 (0.72-1.44)
  Lofgren, et al \[[@B73]\]            Finland          290                59              7    251   55    6    Respiratory Syncytial Virus                No association                       1.06 (0.73-1.66)
  Paulus et al \[[@B74]\]              Canada           97                 9               0    218   17    1    Respiratory Syncytial Virus                No association                       0.84(0.37-1.91)
                                                                                                                 **Sepsis**                                                                      0.81 (0.42-1.56)
  Ahmad-Nejad et al \[[@B75]\]         Germany          99                 12              1    31    6     1    Sepsis (ICU)                               No association                       1.72 (0.64-4.63)
  Carregaro et al \[[@B76]\]           Brazil           178                26              1    88    9     0    Sepsis (ICU)                               No association                       0.71 (0.33-1.56)
  Feterowski et al \[[@B77]\]          Germany          135                19              0    143   10    0    Sepsis (ICU)                               No association                       0.51 (0.23-1.19)
                                                                                                                 **Tuberculosis**                                                                1.18 (0.80-1.73)
  Najmi et al \[[@B78]\]               India            206                44              0    95    34    6    Tuberculosis                               Increased association                **2.00 (1.23-3.25)**
  Newport et al \[[@B79]\]             Gambia           235                58              5    241   62    4    Tuberculosis                               No association                       1.01(0.69-1.49)
  Sanchez, et al \[[@B80]\]            Colombia         270                29              1    429   36    1    Tuberculosis                               No association                       0.78 (0.47-1.28)
  Selvaraj et al \[[@B81]\]            South India      151                53              3    153   47    4    Tuberculosis                               No association                       0.91 (0.59-1.40)
  Rosas-Taraco et al \[[@B82]\]        Mexico           110                4               0    94    10    0    Tuberculosis                               No association                       2.70 (0.87-8.39)
                                                                                                                 **UTI**                                                                         1.41 (0.70-2.84)
  Akil, et al \[[@B83]\]               Turkey           79                 14              0    97    14    1    UTI-children                               No association                       0.85 (0.39-1.84)
  Ertan, et al \[[@B84]\]              Turkey           29                 1               0    28    2     0    UTI-children                               No association                       1.70 (0.22-13.37)
  Karoly et al \[[@B85]\]              Hungary          218                17              0    88    15    0    UTI-children                               Increased risk                       2.18 (1.06-4.52)

10.1371/journal.pone.0081047.t002

###### Genotypic frequencies reported for the *TLR4* 1196 C\>TSNP and association with disease outcome; significant effects are in bold; outcomes that have been studied more than once have been grouped together in the table, with the overall effect described in the shaded area.

                                                     Control Genotype   Case Genotype                                                                                                                             
  --------------------------------- ---------------- ------------------ --------------- --- ----- ---- --- ------------------------------------------ ----------------------------------------------------------- --------------------------------------
  Goepfert et al \[[@B86]\]         United States    316                28              0   435   21   0   Bacterial Vaginosis in Pregnant            Protective                                                  **0.55 (0.31-0.98)**
  Laisk et al \[[@B33]\]            Estonia          287                35              1   61    9    0   *C. trachomatis*(women)                    No association                                              1.24 (0.58-2.67)
  Szebeni et al \[[@B34]\]          Hungary          108                10              0   37    4    0   NecEnterocolitis in LBW infants            No association                                              1.26 (0.39-4.00)
  Lee, et al \[[@B35]\]             United States    395                64              4   89    18   1   Gram --ve infections in liver transplant   No association                                              1.23 (0.71-2.15)
  Achyut et al \[[@B52]\]           India            188                11              1   115   9    6   H pylori                                   No association                                              2.08 (0.95-4.54)
  Ajdary, et al \[[@B36]\]          North Iran       74                 1               0   105   21   2   Leishmaniasis (Cutaneous)                  Increased risk of infection                                 **10.14 (1.90-54.16)**
  Rasouli et al \[[@B37]\]          Iran             137                18              0   112   9    1   Leishmaniasis (Visceral)                   No association                                              0.67 (0.30-1.49)
  Bochud et al \[[@B38]\]           East Africa      179                15              1   407   8    0   Leprosy                                    Protective                                                  **0.23 (0.10-0.55)**
  West, et al \[[@B39]\]            Thailand         1379               22              1   486   3    0   Meliodosis                                 No association**^[*†*](#ngtab2.1){ref-type="table-fn"}^**   0.43 (0.14-1.33) \[0.41(0.13-1.25)\]
  Verma, et al \[[@B40]\]           India            140                9               1   114   25   1   Neurocysticercosis                         Increased risk                                              **3.13 (1.46-6.73)**
  Montes et al \[[@B41]\]           Spain            133                22              0   67    10   3   Osteomyelitis                              Increased risk                                              1.19 (0.57-2.47)
  Mrazek et al \[[@B44]\]           Czechoslovakia   219                33              0   88    10   0   Prosthetic joint infection                 No association                                              0.78 (0.38-1.63)
  Ahmad-Nejad et al \[[@B75]\]      Germany          98                 13              1   31    6    1   Sepsis (ICU)                               No association                                              1.58 (0.60-4.23)
  Yuan et al \[[@B45]\]             Australia        365                43              1   82    3    0   S. pneumoniae                              Protective                                                  0.36 (0.12-1.09)
  Liadaki, et al \[[@B46]\]         Greece           192                30              0   99    6    0   Tonsillar Disease (H.influenzae)           Protective                                                  **0.42 (0.17-1.00)**
  Liadaki, et al \[[@B46]\]         Greece           262                27              0   29    9    0   Tonsillar Disease (S.pyogenes)             Increased risk                                              **3.12 (1.36-7.13)**
  Bhuvanendran, et al \[[@B47]\]    Malaysia         242                8               0   282   22   0   Typhoid Fever                              Increased Risk                                              **2.26 (1.01-5.07)**
  Hawn et al \[[@B49]\]             United States    277                35              4   589   69   0   UTI - Women                                No association                                              0.83 (0.55-1.26)
                                                                                                           **Chagas Disease**                                                                                     1.03 (0.49-2.18)
  Weitzel, et al \[[@B50]\]         Northern Chile   42                 3               0   114   11   0   Chagas Disease                             No association                                              1.19 (0.35-4.14)
  Zafra et al \[[@B51]\]            Colombia         282                9               0   267   8    0   Chagas disease                             No association                                              0.95 (0.37-2.42)
                                                                                                           **Malaria**                                                                                            1.30 (0.64-2.65) 
  Zakeri, et al \[[@B55]\]          Iran             270                50              0   271   49   0   Malaria (all ages)                         No association                                              0.98(0.64-1.50)
  Mockenhaupt et al \[[@B56]\]      Ghana            283                7               0   550   28   2   Malaria (pregnancy)                        Overall susceptibility not studied                          2.05 (0.91-4.62)
                                                                                                           **Periodontitis (aggressive)**                                                                         0.78(0.42-1.65) 
  Brett et al \[[@B61]\]            England          78                 17              0   46    3    0   Aggressive periodontitis                   No association                                              0.35 (0.11-1.16)
  Emingil et al \[[@B62]\]          Turkey           148                7               0   88    2    0   Aggressive periodontitis                   No association                                              0.57 (0.13-2.41)
  Noack et al \[[@B64]\]            Germany          71                 9               0   100   11   0   Aggressive periodontitis                   No association                                              0.86 (0.35-2.13)
  Schulz et al \[[@B65]\]           Germany          73                 7               0   52    8    0   Aggressive periodontitis                   No association                                              1.58 (0.56-4.47)
                                                                                                           **Periodontitis (chronic)**                                                                            1.12 (0.83-1.52)
  Brett et al \[[@B61]\]            England          78                 17              0   50    4    0   Chronic periodontitis                      No association                                              0.41 (0.14-1.22)
  Reddy et al \[[@B87]\]            South India      59                 1               0   56    3    1   Chronic periodontitis                      No association                                              2.77 (0.42-18.48)
  Schulz et al \[[@B65]\]           Germany          73                 7               0   67    7    0   Chronic periodontitis                      No association                                              1.09 (0.38-3.14)
  IzakovicaHolla et al \[[@B69]\]   Czechoslovakia   196                22              0   147   24   0   Chronic periodontitis                      No association                                              1.45 (0.79-2.67)
  Berdeli et al \[[@B70]\]          Turkey           101                5               0   80    3    0   Chronic periodontitis                      No association                                              0.81(0.20-3.16)
  James et al \[[@B63]\]            West Europe      74                 18              0   73    20   1   Chronic periodontitis                      No association                                              1.16 (0.58-2.32)
  Noack et al \[[@B67]\]            Germany          68                 8               0   96    12   0   Chronic periodontitis                      No association                                              1.04 (0.42-2.61)
  Laine et al \[[@B71]\]            Netherlands      90                 8               1   90    10   0   Chronic periodontitis                      No association                                              1.15 (0.46-2.93)
  Folwaczny et al \[[@B72]\]        Germany          235                9               0   233   11   0   Chronic periodontitis                      No association                                              1.22(0.51-2.93)
                                                                                                           **Tuberculosis**                                                                                       1.07 (0.81-1.42)
  Najmi et al \[[@B56]\]            India            206                43              1   105   26   4   Tuberculosis                               No association                                              1.37 (0.82-2.28)
  Sanchez, et al \[[@B80]\]         Colombia         272                26              1   429   36   1   Tuberculosis                               No association                                              0.87 (0.52-1.46)
  Selvaraj et al \[[@B81]\]         South India      152                46              5   150   49   4   Tuberculosis                               No association                                              1.04 (0.68-1.61)

genotypic frequencies of controls that did not satisfy Hardy Weinberg Equilibrium, \[effects in brackets after correction of HWE deviations\].

TLR4 896 A\>G and disease susceptibility {#s3.1}
----------------------------------------

For outcomes with more than 1 available study, a meta-analysis was performed for chronic periodontitis (10 studies) \[[@B61],[@B63],[@B65]-[@B72]\], *Helicobacter pylori* infection (2 studies) \[[@B52],[@B53]\], malaria (3 studies) \[[@B54]-[@B56]\], meningococcal disease (4 studies) \[[@B57]-[@B60]\], sepsis (3 studies) \[[@B75]-[@B77]\], respiratory syncytial virus (2 studies) \[[@B73],[@B74]\], tuberculosis (5 studies) \[[@B78]-[@B82]\] and urinary tract infections in children (3 studies) \[[@B83]-[@B85]\]. Combined effects were also calculated for all Gram negative infections \[[@B30],[@B31],[@B33],[@B35],[@B39],[@B46],[@B47],[@B52],[@B53],[@B57]-[@B60]\], all Gram positive infections \[[@B43],[@B45],[@B46]\] and all parasitic infections \[[@B36],[@B37],[@B40],[@B50],[@B51],[@B54]-[@B56]\] ([table 3](#pone-0081047-t003){ref-type="table"}). A significant risk was found for all parasitic infections combined (OR~G~ 1.59; 95% CI 1.05-2.42, effect derived from Asian, African and South American populations; [Figure 1](#pone-0081047-g001){ref-type="fig"}) and malaria (OR~G~ 1.31; 95% CI 1.04-1.66, a combined effect for African and Asian studies; [Figure 2](#pone-0081047-g002){ref-type="fig"}) . The effect on malaria was of marginal significance across African studies \[[@B54],[@B56]\] (OR~G~ 1.29; 95% CI 0.99-1.69). All other effects were insignificant, namely all Gram negative infections (OR~G~ 1.10; 95% CI 0.90-1.38), all Gram positive infections (OR~G~ 1.28; 95% CI 0.43-3.81), Chagas disease (OR~G~ 1.06; 95% CI 0.53-2.14) , *H. pylori* (OR~G~ 0.91; 95% CI 0.61-1.36), meningococcal disease (OR~G~ 1.10; 95% CI 0.90-1.34), aggressive or chronic periodontitis (OR~G~ 1.04; 95% CI 0.53-2.04 and OR~G~ 0.94; 95% CI 0.75-1.18, respectively), respiratory syncytial virus (OR~G~1.02; 95% CI 0.72-1.44), sepsis (OR~G~ 0.81; 95% CI 0.41-1.56) and tuberculosis (OR~G~ 1.18; 95% CI 0.80-1.73). The meta-analysis results are summarized in [Table 3](#pone-0081047-t003){ref-type="table"}. Statistical heterogeneity varied from absent to moderate. The Harbord's test indicated that there is no differential magnitude of effect in large versus small studies for all outcomes (p≥0.05). Across populations of European ancestry, the risk of meningococcal disease \[[@B57]-[@B59]\] (OR~G~ 1.12; 95% CI 0.85-1.49) and chronic periodontitis (excluding the two non-European studies \[[@B66],[@B68]\]; OR~G~ 1.06; 95% CI 0.53-2.14) remained insignificant. The effects on meningococcal disease and aggressive periodontitis did not alter after removing from analysis the two studies not in HWE equilibrium (data not shown) \[[@B58],[@B62]\]. Effects on tuberculosis remained insignificant across Indian \[[@B78],[@B81]\] (OR~G~ 1.34; 95% CI 0.62-2.90) or S. American \[[@B80],[@B82]\] populations (OR~G~ 1.30; 95% CI 0.39-4.33). For outcomes with a single available study, a significant risk was present for brucellosis (OR~G~ 2.66; 95% CI 1.66-4.27) \[[@B30]\], cutaneous leishmaniasis (OR~G~ 7.22; 95% CI 1.91-27.29) \[[@B36]\], neurocysticercosis (OR~G~ 4.39; 95% CI 2.53-7.61) \[[@B40]\], and typhoid fever (OR~G~ 2.51; 95% CI 1.18-5.34) \[[@B47]\]. All the significant single-study effects are summarized in [Table 4](#pone-0081047-t004){ref-type="table"}.

10.1371/journal.pone.0081047.t003

###### Summary of disease associations derived from meta-analysis of case-control studies.

  **Disease Outcome**         **Studies**   **Polymorphism**   **Effect (OR~G~ ; 95% CI)**   **P~Q~**   **I^2^**   **P~H~**
  --------------------------- ------------- ------------------ ----------------------------- ---------- ---------- ----------
  All Gram - infections       13            *TLR4 896 A\>G*    1.10 (0.90-1.38)              0.01       52%        0.32
                              6             *TLR4 1196 C\>T*   1.11 (0.66-1.87)              0.02       61%        0.59
  *Helicobacter pylori*       2             *TLR4 896 A\>G*    0.91 (0.61-1.36)              0.79       \-         \-
  Meningococcal Disease       4             *TLR4 896 A\>G*    1.10 (0.90-1.34)              0.43       0          0.93
  All Gram + infections       3             *TLR4 896 A\>G*    1.28 (0.43-3.81)              0.01       77%        \-
                              2             *TLR4 1196 C\>T*   1.09(0.13-9.09)               0.002      \-         \-
  All parasitic infections    8             *TLR4 896 A\>G*    1.59 (1.05-2.42)              \<0.001    72%        0.72
                              7             *TLR4 1196 C\>T*   1.50 (0.88-2.56)              0.01       64%        0.5
  Chagas Disease              2             *TLR4 896 A\>G*    1.06 (0.53-2.14)              0.82       \-         \-
                              2             *TLR4 1196 C\>T*   1.03 (0.49-2.18)              0.76       \-         \-
  Malaria                     3             *TLR4 896 A\>G*    1.31 (1.04-1.66)              0.71       0          \-
                              2             *TLR4 1196 C\>T*   1.30 (0.64-2.65)              0.11       \-         \-
  Periodontitis(Aggressive)   5             *TLR4 896 A\>G*    1.04 (0.53-2.04)              0.07       52%        0.16
                              4             *TLR4 1196 C\>T*   0.78 (0.42-1.65)              0.29       20%        0.92
  Periodontitis (Chronic)     10            *TLR4 896 A\>G*    0.94 (0.75-1.18)              0.68       0          0.74
                              9             *TLR4 1196 C\>T*   1.12 (0.83-1.52)              0.74       0          0.93
  RSV                         2             *TLR4 896 A\>G*    1.02 (0.72-1.44)              0.61       \-         \-
  Sepsis                      3             *TLR4 896 A\>G*    0.81 (0.41-1.56)              0.16       45%        \-
  Tuberculosis                5             *TLR4 896 A\>G*    1.18(0.80-1.73)               0.03       63%        0.43
                              3             *TLR4 1196 C\>T*   1.07 (0.81-1.42)              0.47       0          \-
  UTI (Children)              3             *TLR4 896 A\>G*    1.41 (0.70-2.84)              0.21       35%        \-

P~Q=~ p value for Q homogeneity test; P~H~= p value for Harbord's small study effects test, -=not applicable

![All parasitic infections: Random effects (RE) generalized odds ratio (OR~G~) estimates with the corresponding 95% confidence interval (CI) for the variant TLR4 896 A\>*G*.\
The horizontal axis is plotted on a log scale.](pone.0081047.g001){#pone-0081047-g001}

![Malaria: Random effects (RE) generalized odds ratio (OR~G~) estimates with the corresponding 95% confidence interval (CI) for the variant TLR4 896 A\>*G*.\
The horizontal axis is plotted on a log scale.](pone.0081047.g002){#pone-0081047-g002}
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###### Summary of significant associations with disease outcomes, derived from single case-control studies.

  **Study**                **Population**   **Disease Outcome**               **Polymorphism**   **OR~G~ (95% CI**)
  ------------------------ ---------------- --------------------------------- ------------------ --------------------
  Goepfert \[[@B86]\]      USA              Bacterial vaginosis (pregnancy)   *TLR4 1196 C\>T*   0.55 (0.31-0.98)
  Rezazadeh\[[@B30]\]      Iran             Brucellosis                       *TLR4 896 A\>G*    2.66 (1.66-4.27)
  Ajdary \[[@B36]\]        Iran             Cutaneous leishmaniasis           *TLR4 896 A\>G*    7.22 (1.91-27.29)
                                                                              *TLR4 1196 C\>T*   10.14 (1.90-54.16)
  Bochud \[[@B38]\]        East Africa      Leprosy                           *TLR4 896 A\>G*    0.36 (0.22-0.60)
                                                                              *TLR4 1196 C\>T*   0.23(0.10-0.55)
  Verma \[[@B40]\]         India            Neurocysticercosis                *TLR4 896 A\>G*    4.39 (2.53-7.61)
                                                                              *TLR4 1196 C\>T*   3.13 (1.46-6.73)
  Liadaki \[[@B46]\]       Greece           *H.influenzae* (tonsillitis)      *TLR4 1196 C\>T*   0.42 (0.17-1.00)
  Liadaki \[[@B46]\]       Greece           *S.pyogenes* (tonsillitis)        *TLR4 896 A\>G*    2.93 (1.24-6.93)
                                                                              *TLR4 1196 C\>T*   3.12 (1.36-7.13)
  Bhuvanedran \[[@B47]\]   Malaysia         Typhoid fever                     *TLR4 896 A\>G*    2.51 (1.18-5.34)
                                                                              *TLR4 1196 C\>T*   2.26 (1.01-5.07)
  Yin \[[@B48]\]           China            UTI (Adults)                      *TLR4 896 A\>G*    1.98 (1.04-3.98)

Of note, all these effects were derived from Asian studies. Increased risk for tonsillar infection due to *Streptococcus pyogenes* (OR~G~ 2.93; 95% CI 1.24-6.93) \[[@B46]\] was noted in the Greek pediatric population, as was an increased risk for urinary tract infections in adults (OR~G~ 1.98; 95% CI 1.04-3.98) in a Chinese population \[[@B48]\]. Interestingly, not all outcomes were negative and the *TLR4* 896 A\>*G* polymorphism was associated with significant protection against leprosy (OR~G~ 0.36; 95% CI 0.22-0.60) in East Africa \[[@B38]\].

The use of the OR~G~ metric resulted in more conservative estimates of associations, as two reportedly significant associations (1 reporting increased risk for Gram-negative osteomyelitis \[[@B41]\] and 1 reporting a protective effect for *Streptococcus pneumoniae* in children \[[@B45]\]) were downgraded to non-significant. Six control populations deviated for HWE equilibrium \[[@B30],[@B35],[@B39],[@B53],[@B58],[@B62]\], and associations of TLR4 variants with disease were readdressed after correcting genotypes with their expected frequencies. These effects did not change (they appear in brackets in [Tables 1](#pone-0081047-t001){ref-type="table"},[2](#pone-0081047-t002){ref-type="table"}). Specifically, the association of *TLR4* 896 A\>*G* and brucellosis \[[@B30]\] remained significant after HWE correction (OR~G~ 2.69; 95% CI 1.67-4.33).

TLR4 1196 C\>T and disease susceptibility {#s3.2}
-----------------------------------------

A meta-analysis of GAS was performed for malaria (2 studies) \[[@B55],[@B56]\], aggressive periodontitis (4 studies) \[[@B61],[@B62],[@B64],[@B65]\], chronic periodontitis (9 studies) \[[@B61],[@B63],[@B65],[@B67],[@B69]-[@B72],[@B87]\], and tuberculosis (3 studies) \[[@B78],[@B80],[@B81]\] and revealed no significant effects. Statistical heterogeneity varied from absent to moderate. Specifically, the combined effects were OR~G~ 1.30 (95% CI 0.64-2.65) for malaria, OR~G~ 0.78 (95% CI 0.42-1.65) for aggressive and OR~G~ 1.12 (0.83-1.52) for chronic periodontitis, and OR~G~ 1.07 (95% CI 0.81-1.42) for tuberculosis. Effects were also insignificant for all Gram negative infections combined \[OR~G~ 1.11 (95% CI 0.66-1.87)\]\[[@B33],[@B35],[@B39],[@B46],[@B47],[@B52]\], all Gram positive infections combined \[OR~G~ 1.09 (95% CI 0.13-9.09)\] \[[@B45],[@B46]\] and all parasitic infections combined \[OR~G~ 1.50 (95% CI 0.88-2.56)\] \[[@B36],[@B37],[@B40],[@B50],[@B51],[@B55],[@B56]\]. The meta-analysis results are summarized in [Table 3](#pone-0081047-t003){ref-type="table"}. The Harbord's test indicated that there is no differential magnitude of effect in large versus small studies for all outcomes (p≥0.05).

For outcomes with a single available study, a significant risk was present for cutaneous leishmaniasis in Iran (OR~G~ 10.14; 95% CI 1.90-54.16) \[[@B36]\], neurocysticercosis in India (OR~G~ 3.10; 95% CI 1.45-6.67) \[[@B40]\], *S. pyogenes* tonsillar disease in Greece (OR~G~ 3.12; 95% CI 1.36-7.13) \[[@B46]\] and typhoid fever in Malaysia (OR~G~ 2.26; 95% CI 1.01-5.07) \[[@B47]\]. A significant protection was conferred for bacterial vaginosis in pregnancy (OR~G~ 0.55;95% CI 0.31-0.98) in the United States (notably, African Americans comprised 78% of the cases) \[[@B86]\], leprosy in East Africa (OR~G~ 0.23; 95% CI 0.10-0.55) \[[@B38]\], and *Haemophilus influenzae* tonsillar disease in a Greek pediatric population (OR~G~ 0.42; 95% CI 0.17-1.00) \[[@B46]\]. The significant results are summarized in [Table 4](#pone-0081047-t004){ref-type="table"}. Only 1 control population deviated from HWE equilibrium that assessed the risk of meliodosis \[[@B39]\], a risk that did not change after correction with the expected genotype frequencies ([Table 2](#pone-0081047-t002){ref-type="table"}). Two reportedly significant associations for Gram-negative osteomyelitis (increased risk) and *S. pneumoniae* (protection) were not confirmed in this analysis with the use of the OR~G~ metric.

The significant effects were unidirectional and similar in magnitude when both *TLR4* 896 A\>*G* and 1196 C\>*T* were examined ([Table 4](#pone-0081047-t004){ref-type="table"}), that is if *TLR4* 896 A\>*G* was protective then 1196 C\>*T* was also protective. When *TLR4* 896 A\>*G* increased risk, then 1196 C\>*T* increased risk. Specifically, the point estimates for 896 A\>*G* and 1196 C\>*T* variants were (respectively): 7.22 and 10.14 for cutaneous leishmaniasis, 4.39 and 3.13 for neurocysticercosis, 2.93 and 3.12 for *S. pyogenes* tonsillar disease, 2.51 and 2.26 for typhoid fever, 0.36 and 0.23 for leprosy. An exception to the rule was *H. influenzae* tonsillar disease, where the protective effect of *TLR4* 896 A\>*G* did not reach statistical significance (OR~G~ 0.47; 95% CI 0.19-1.14), while 1196 C\>*T* showed significant association (OR~G~ 0.42; 95% CI 0.17-1.00).

Discussion {#s4}
==========

We performed a systematic literature review to address the potential association of 2 common TLR4 single nucleotide polymorphisms (*TLR4 896 A\>G, TLR4 1196 C\>T*) with infectious diseases. An increased risk was documented for all parasitic infections combined, malaria \[[@B54]-[@B56]\], brucellosis \[[@B30]\], cutaneous leishmaniasis \[[@B36]\], typhoid fever \[[@B47]\], neurocysticercosis \[[@B40]\] and adult urinary tract infections \[[@B48]\]. Interestingly, all these effects were reported in populations of Asian descent, with the exception of parasitic infections and malaria where the effect was a combined effect from Asian, African and South American populations. This finding is more striking when we consider that European populations comprised the majority of GAS data (28 out of 59 studies, 48%) and a significant risk was found only for TLR4 polymorphisms and *S. pyogenes* tonsillitis among Greek children \[[@B46]\]. Another notable finding is that, for some infections, these single nucleotide polymorphisms were associated with lower infection rates. Overall, these effects sum to a total of 11 significant SNPs-disease associations that represent almost one third (30%) of all outcomes addressed in the eligible studies and there was consistency of effects (risk or protection) between 896 A\>*G* and 1196 C\>*T* variants when both associations were studied.

In this study we utilized the generalized odds ratio (OR~G~) metric to quantify the magnitude of associations. This metric provides a straightforward interpretation of the relative risk effect, based solely on genotype distribution \[[@B20]\]. The generalized odds ratio overcomes this problem by directly quantifying the magnitude of association of a gene with disease \[[@B20]\]. Implementing the OR~G~ obviates the need for selecting, estimating and interpreting individual genotype contrasts (dominant, recessive and co-dominant) and their effect. OR~G~ can also be used in meta-analysis of GAS to summarize effects and produce robust results, avoiding the shortcomings of multiple model testing, namely the lack of biologic justification and non-independency of effects \[[@B20],[@B88],[@B89]\]. For example, for *TLR4* 896 A\>*G* association with malaria, the combined OR~G~ showed that the probability of having malaria might be 31% higher for subjects having higher mutational load relative to those with lower mutational load (subjects who are homozygous for *G* allele have the highest mutational load, those homozygous for A allele have the lowest, and heterozygous have an intermediate level). The application of the OR~G~ metric also resulted in a more conservative estimate of associations, given that associations for infections such as osteomyelitis (39) and *S. pneumonia* (43) were downgraded to insignificant. The associations derived from tuberculosis data were insignificant similar to those reported \[[@B90]\].

In our analysis, TLR4 polymorphisms were associated with susceptibility to a diverse spectrum of infections including Gram-negative, Gram-positive bacteria as well as parasitic infections, such as cutaneous leishmaniasis and neurocysticercosis. This wide spectrum of associations correlates with the spectrum of recognition molecules by TLR4. Indeed, TLR4 is involved in induction of cell-mediated immunity to *Brucella abortus* in mice \[[@B7]\] and TLR4 signaling also upregulates macrophage anti-leishmanial activity \[[@B91]\]. Similarly, binding of the *Salmonella typhi* porin OmpS1 to TLR4 leads to overexpression of MHCII and CD40 molecules and activation of dendritic cells \[[@B92]\]. TLR4 can recognize LPS of Gram-negative bacteria \[[@B3],[@B4]\], glycans of the helminth *Taenia solium* \[[@B93]\] as well as the fusion protein of respiratory syncytial virus\[[@B9]\].

Interestingly, our analysis also confirmed that these polymorphisms are also protective for certain types of infection, such as leprosy. It is not clear why such polymorphisms confer increased susceptibility to some infection, but protect from others. It could be speculated that in some infections the immune response leads to an inflammatory response that is protective, whereas in others such response may be essential in the pathogenesis of the infectious process. An example is *Mycobacterium leprae* where the TLR4-mediated immune response to the pathogen may modulate inflammatory processes that influence disease manifestations but are not attributable to direct stimulation by M. leprae. Indeed, Bochud et al \[[@B38]\] found that the stimulation of monocytes with M. leprae inhibited their subsequent response to TLR4 stimulation with LPS.

Among Indo-European populations, 6-14% of the individuals are double heterozygous for both polymorphisms \[[@B94]\]. It is suggested that the double heterozygous *TLR4* 896 A\>*G*/TLR4 1196 C\>*T* haplotype does not functionally differ from wild type TLR4. Therefore, co-segregation may result in a functionally neutral phenotype and, as seen in European populations, lead to the lack of significant associations. Conversely, *TLR4* 896 A\>*G* was frequently found (10-18%) among African populations, with only 2% having *TLR4* 1196 C\>*T* co-segregation. Two studies (on typhoid fever and leprosy) indicated weak linkage disequilibrium in Malaysian \[[@B47]\] and East African populations \[[@B38]\]. These differences between Europeans (co-segregation) compared to Asian and African population (lack of co-segregation) may explain why the majority of significant associations were noted for endemic diseases of Asia and Africa.

Our analysis on the impact of these polymorphisms in periodontitis illustrates the different impact of polymorphisms based on the population. More specifically, despite the bulk of studies on aggressive and chronic periodontitis, TLR4 variants did not show any significant association, even though TLR4 has been shown to be overexpressed in gingival epithelial cells and gingival fibroblasts \[[@B95]-[@B97]\] in association with periodontal inflammation involving pathogens related to periodontitis, such as *Porphyromonas gingivalis*, *Fusobacterium nucleatum* and *Aggregatibacter actinomycetemcomitans* \[[@B98]-[@B101]\]. One possible explanation is that this finding was because all relevant studies were almost exclusively confined to European ancestry populations and the lack of susceptibility may be related to the strong linkage disequilibrium, that is the non-random association between 896 A\>*G and* 1196 C\>*T* in Europeans \[[@B94]\].

Importantly, our analysis highlights the need to evaluate the impact of these polymorphisms in different populations and various clinical conditions. Moreover, the absence of significant associations in meta-analysis data for periodontitis, tuberculosis, meningococcal disease and sepsis, signifies that the functional alterations related to polymorphic TLR4 variants may not be critical to produce the clinical phenotype. Lack of reproducibility stands as a barrier for conclusive evidence, and design, sample size and environmental and genetic heterogeneity between populations may affect results. Finally, the presence of a significant effect may rely on the magnitude of functional expression of TLR4. Protection or risk may be moderated by the level of TLR4 functional expression, which is modulated by TLR4 polymorphism and MD-2 presence \[[@B14],[@B15]\]. Therefore, it is essential to explore whether MD-2 is important in the response to some infections, but not others, or that levels of TLR4 vary in one infection compared to another.

The heterogeneity of the populations studied along with multiple endpoints should also be considered as potential study limitation that may influence statistical power. Moreover, different populations mount diverse immunologic responses and the clinical relevance of polymorphisms is not always straightforward. The lack of association for a disease phenotype highlights that gene-to-gene interactions and gene-environment interactions may be influential parameters of disease association. Case-control design of individual GAS precludes adjusted analysis for gene-gene-environment interactions and may have reduced the efficiency of genetic risk estimates, though it is unlikely to inflate false-positive results \[[@B89]\].

Despite these limitations, genetic markers of immune response such as TLR4 variants, are valuable not only to classify high-risk patients based on disease susceptibility but also to predict disease severity and other sequelae. The associations of TLR4 896A\>G with hearing loss in survivors of bacterial meningitis \[[@B102]\] and the increased risk of tympanostomy among toddlers with history of bronchiolitis \[[@B103]\] are indicative examples.

In conclusion, our analysis highlights the complex effect of TLR variants in susceptibility to infectious disease. Some of the effects, such as in malaria, are validated in a variety of studies, whereas single case-control studies should be cautiously interpreted until more information on the specific outcomes is added. Taken in their totality, our results indicate that depending on the infection and the population studied, the same polymorphism may be associated with risk, protection or have no effect. In this context, our analysis provides the rationale for understanding the protective or adverse effect of TLR4 polymorphisms and may provide a basis to explain the maintenance of these polymorphisms.

Supporting Information
======================

###### 

**PRISMA checklist.**

(DOC)

###### 

Click here for additional data file.

###### 

**Flow diagram of meta-analysis.**

(DOCX)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**EM, M. D., Ph.D is a PLOS ONE Editorial Board member. This does not alter the authors\' adherence to all the PLOS ONE policies on sharing data and materials.

[^2]: Analyzed the data: PDZ MLP. Contributed reagents/materials/analysis tools: EZ. Wrote the manuscript: PDZ MLP JK EZ EM. Search strategy, data selection, data extraction: PDZ MLP.
